AABB to Explore Expanding Quality Systems Assessments During CGT Summit

Jeff Wren, MBA, CABP, AABB's vice president of biotherapies, will discuss considerations for extending quality systems assessments beyond traditional pathways during the 2026 Cell & Gene Therapy Summit, taking place July 6-8 in Boston.

As novel cell therapies move beyond academic medical centers, ensuring quality has become increasingly critical. Wren will discuss how independent, standards-based quality system assessments provide a scalable framework for organizations that support cellular therapies but fall outside traditional accreditation pathways, enabling the field to expand without compromising quality or patient safety.

The session will take place at 12 p.m. ET, July 8. Attendees interested in connecting with Wren during the meeting can visit AABB's virtual booth or connect via email to schedule a conversation.